Sana Biotechnology (NASDAQ:SANA) Shares Gap Down to $4.66

Sana Biotechnology, Inc. (NASDAQ:SANAGet Rating) gapped down before the market opened on Tuesday . The stock had previously closed at $4.66, but opened at $4.48. Sana Biotechnology shares last traded at $4.53, with a volume of 179 shares trading hands.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group reduced their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Thursday, November 3rd.

Sana Biotechnology Stock Up 2.3 %

The business’s 50-day simple moving average is $5.65 and its 200 day simple moving average is $6.18. The firm has a market capitalization of $921.21 million, a P/E ratio of -2.99 and a beta of 0.41.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. National Bank of Canada FI increased its stake in shares of Sana Biotechnology by 2,162.2% in the second quarter. National Bank of Canada FI now owns 4,185 shares of the company’s stock worth $27,000 after buying an additional 4,000 shares during the period. Point72 Hong Kong Ltd purchased a new position in shares of Sana Biotechnology in the third quarter worth $58,000. Quantamental Technologies LLC purchased a new position in shares of Sana Biotechnology in the third quarter worth $70,000. Teacher Retirement System of Texas purchased a new position in shares of Sana Biotechnology in the second quarter worth $81,000. Finally, XTX Topco Ltd purchased a new position in shares of Sana Biotechnology in the first quarter worth $86,000. 64.49% of the stock is owned by hedge funds and other institutional investors.

About Sana Biotechnology

(Get Rating)

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.

Featured Stories

Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.